Phenibutan—an Illegal Food Supplement With Psychotropic Effects and Health Risks.

Phenibut has been associated with significant overdoses, but no fatalities have been reported in Western Europe, suggesting a need for further awareness and research on its risks.

Summary and findings

This review discusses the psychotropic effects and health risks associated with Phenibut, a GABA analog. It highlights inquiries and cases reported to a poison information center regarding Phenibut and its toxicity. The review indicates that while there have been overdoses, no fatalities have been reported in Western Europe.

Abstract

<h4>Background</h4>Phenibut (β-phenyl-γ-aminobutyric acid) is an analog of the neurotransmitter gamma-aminobutyric acid (GABA). Like abapentin and pregabalin, it inhibits α2-δ-subunits of voltagedependent presynaptic calcium channels. The potential harm resulting from the use of these gabapentinoids is currently a matter of debate.<h4>Methods</h4>This review is based on pertinent publications retrieved by a selective literature search and on cases reported to the Giftinformationszentrum-Nord (GIZ-Nord), a poison information center at the University of Göttingen, Germany.<h4>Results</h4>Phenibut is a prescription drug in Russia but its production, possession, use, trafficking, or administration is illegal in Germany. The phenibut toxicity syndrome resembles that of gabapentinoids and GABA mimetics: benzodiazepine-like with - drawal symptoms including epileptic seizures, delirium and paradoxical activation have been described, as have cases of abuse and dependence. A few cases of use in the setting of multidrug abuse, and of phenibut-related death, have been described to date in the USA. The GIZ-Nord received 17 inquiries about phenibut, 55 about gabapentin, and 126 about pregabalin over the period 2008-2022. Over the same period, the GIZ-Nord was informed of 1207 cases involving Z substances and 4324 involving benzodiazepines. In the majority of the registered intoxications, including those with phenibut, the symptoms were mild. Overdoses of phenibut (2-100 g) were reported in 15 of the 17 cases; 8 of the persons who had taken an overdose were somnolent. In such cases, observation in intensive care was recommended. Respiratory depression or coma was not encountered in any case, not even in the patient who had taken 100 g of phenibut.<h4>Conclusion</h4>Phenibut causes symptoms resembling those of gabapentinoid and benzodiazepine use. There have been reports of phenibut use in combination with other psychotropic drugs; in particular, its use together with opiates could increase the risk of coma and respiratory depression. No deaths due to phenibut intoxication have been published in Germany or elsewhere in Western Europe, although such cases may have been overlooked, as this drug is still largely unknown to Western medicine.

Key findings

• Not reported in abstract.
• Not reported in abstract.
• Not reported in abstract.

Limitations

• Not reported in abstract.
• Not reported in abstract.
• Not reported in abstract.

Elsewhere in the NA Selank Amidate (N-Acetyl Selank Amidate) corpus